HeartBeam Partners With HeartNexus to Expand Remote Cardiac Monitoring Services

HeartBeam has announced a strategic partnership with HeartNexus Inc. to deliver comprehensive remote cardiology services. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional healthcare facilities. This partnership represents a significant advancement in making specialized cardiac care more accessible to patients regardless of their location or time of day.

The integration allows patients using HeartBeam's technology to capture 30-second, cable-free ECG recordings whenever symptoms occur. These recordings are immediately transmitted to HeartNexus cardiologists for professional interpretation. HeartNexus brings specialized expertise in cardiac test interpretation, peer consultations, and telemedicine visits through their network of board-certified cardiologists. This real-time interpretation capability addresses a critical gap in cardiac care where timely diagnosis can significantly impact patient outcomes.

Robert Eno, CEO of HeartBeam, emphasized the strategic importance of this collaboration, stating that working with HeartNexus accelerates their mission to make medical-grade cardiac monitoring accessible beyond the walls of medical facilities. The partnership expands HeartBeam's ecosystem with real-time cardiology feedback and lays the foundation for future integration of AI wellness and wearable features. This expansion aligns with the growing trend toward remote patient monitoring and telehealth services in the healthcare industry.

HeartBeam's core technology platform represents a significant innovation in cardiac monitoring. The company is developing the first cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing these signals into a 12-lead ECG. This technology platform is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence to physicians. The 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review.

The company's intellectual property portfolio includes over 20 issued patents related to technology enablement, providing a strong foundation for continued innovation in remote cardiac monitoring. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. The partnership with HeartNexus represents a strategic move to enhance the value proposition of HeartBeam's technology by combining advanced monitoring capabilities with immediate professional interpretation services.

This collaboration has significant implications for cardiac care delivery, particularly for patients with intermittent symptoms that may not occur during standard medical office hours. The ability to capture and interpret ECG data in real-time outside clinical settings could lead to earlier detection of cardiac conditions and more timely interventions. The integration of these services addresses the growing demand for remote healthcare solutions and positions both companies at the forefront of digital health innovation in cardiology.